JIR
XENT

James Investment Research’s Intersect ENT, Inc XENT Stock Holding History

James Investment Research’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,600
Closed -$63K – 881
2018
Q1 		$63K Buy
1,600
+235
+17% +$8.58K ﹤0.01% 642
2017
Q4 		$44K Hold
1,365
– – ﹤0.01% 665
2017
Q3 		$43K Buy
+1,365
New +$40.4K ﹤0.01% 639

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

James Investment Research's XENT Position: Q2 2018 in Review

James Investment Research sold out of Intersect ENT, Inc (XENT) in Q2 2018, closing a stake of 1,600 shares — an estimated $63K sold.

James Investment Research first reported a position in XENT in Q3 2017 and held it in 3 quarters. The position peaked at $63K in Q1 2018. 160 funds tracked by Wall St. Rank hold XENT as of Q2 2018.

  • James Investment Research reported no remaining Intersect ENT, Inc position as of Q2 2018 after selling out during the quarter.
  • James Investment Research sold 1,600 Intersect ENT, Inc shares in Q2 2018, an estimated $63K.
  • James Investment Research first reported a position in Intersect ENT, Inc in Q3 2017 and held it in 3 quarters.
  • James Investment Research's Intersect ENT, Inc position peaked at $63K in Q1 2018.
  • 160 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2018.

Based on James Investment Research's 13F filing for Q2 2018, filed 19 Jul 2018.